C-C chemokine receptor 4 expression in CD8+ cutaneous T-cell lymphomas and lymphoproliferative disorders, and its implications for diagnosis and treatment Journal Article
| Authors: | Geller, S.; Hollmann, T. J.; Horwitz, S. M.; Myskowski, P. L.; Pulitzer, M. |
| Article Title: | C-C chemokine receptor 4 expression in CD8+ cutaneous T-cell lymphomas and lymphoproliferative disorders, and its implications for diagnosis and treatment |
| Abstract: | Aims: Patients with aggressive CD8+ cutaneous T-cell lymphomas (CTCLs) progress rapidly and respond poorly to therapy. Confounding treatment planning, there is clinicopathological overlap between aggressive CD8+ CTCLs and other lymphoproliferative disorders (LPDs). Hence, improved diagnostic methods and therapeutic options are needed. The aim of this study was to examine C-C chemokine receptor 4 (CCR4) expression as a diagnostic and therapeutic biomarker in CD8+ CTCLs/LPDs. Methods and results: Forty-nine cases (41 patients) with CD8+ CTCLs/LPDs were examined, including CD8+ mycosis fungoides (MF) (n = 14), aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma (AETCL) (n = 8), subcutaneous panniculitis-like T-cell lymphoma (SPTCL) (n = 7), CD30+ LPDs (n = 6), primary cutaneous γδ T-cell lymphoma (GDTCL) (n = 6), and others (n = 8). Immunohistochemical tissue staining was performed with a CCR4 monoclonal antibody on formalin-fixed paraffin-embedded tissue sections. CCR4 immunostaining was graded as percentage infiltrate, i.e. high (>25%) and low (≤25%), and the results were correlated with clinicopathological diagnoses. CCR4 expression was seen in 69% of the studied cases. Any CCR4 positivity was seen in all CD8+ MF cases, in 83% of CD30+ LPD cases, in 75% of AETCL cases, in 33% of GDTCL cases, and in none of the SPTCL cases. High CCR4 expression was seen in 79% of CD8+ MF cases versus 33% of CD30+ LPD cases, in 17% of GDTCL cases, and in 12.5% of AETCL cases. Patients with more advanced MF stage had higher CCR4 expression. Conclusions: CCR4 immunohistochemistry may be an adjunct in distinguishing advanced CD8+ MF from other CD8+ CTCLs/LPDs. Although CCR4 expression may justify therapeutic targeting of this receptor in CD8+ MF, the role of such therapies in other CD8+ CTCLs/LPDs is not yet clear. © 2019 John Wiley & Sons Ltd |
| Keywords: | immunohistochemistry; adolescent; adult; child; clinical article; human tissue; preschool child; protein expression; aged; middle aged; human cell; histopathology; cd8+ t lymphocyte; biological marker; skin biopsy; cell infiltration; monoclonal antibody; tissue section; cutaneous t-cell lymphoma; cutaneous t cell lymphoma; peripheral t cell lymphoma; chemokine; immunotherapy; cytotoxic t lymphocyte; lymphoproliferative disease; cell marker; mycosis fungoides; epstein barr virus; granulomatosis; gamma delta t lymphocyte; ctcl; chemokine receptor ccr4; very elderly; human; male; female; priority journal; article; subcutaneous t cell lymphoma; mogamulizumab; mf; epidermotropic t cell lymphoma |
| Journal Title: | Histopathology |
| Volume: | 76 |
| Issue: | 2 |
| ISSN: | 0309-0167 |
| Publisher: | Wiley Blackwell |
| Date Published: | 2020-01-01 |
| Start Page: | 222 |
| End Page: | 232 |
| Language: | English |
| DOI: | 10.1111/his.13960 |
| PUBMED: | 31355940 |
| PROVIDER: | scopus |
| PMCID: | PMC7577561 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 3 February 2020 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work